Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dermax Co., Ltd
WARNING LETTER
•Dermax Co., Ltd•November 1, 2025

Dermax Co., Ltd – FDA Warning Letter, Nov 1, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Dermax Co., Ltd. on November 3, 2025, following a review of their website, www.dermaxshop.com. The FDA found the company is introducing unapproved new drugs and misbranded drugs, specifically injectable botulinum toxin products such as "Botulax 100U," into U.S. interstate commerce. These actions violate several sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The main issues include offering products that are unapproved new drugs, meaning they lack FDA authorization for safety and effectiveness, and are therefore prohibited from sale. Additionally, the products are considered misbranded because, as prescription-only drugs, they do not bear adequate directions for safe use by a layperson, which is a requirement for their intended use. The FDA emphasized the significant health risks to consumers who purchase these unregulated products, noting potential contamination, counterfeiting, and serious adverse health effects from injectables.

Dermax Co., Ltd. is required to immediately stop selling all unapproved and misbranded drugs to U.S. consumers. The company must submit a written response to the FDA within 15 working days, detailing the specific steps taken to rectify the violations and prevent their recurrence, along with supporting documentation. Non-compliance could result in further legal actions, including product seizure and injunction.

Company
Dermax Co., Ltd
Inspection date
November 1, 2025
Product type
Drugs
Office
Office of Drug Security, Integrity, and Response
Person
  • Sangeeta V. Chatterjee
View Company Profile

ID · 5669f317-6ac3-4ea1-9148-fb75a900e2c1

Violation Codes10
FD&C Act 301(a)FD&C Act 301(d)FD&C Act 503(b)FD&C Act 505(a)21.U.S.C. 331(a)21 U.S.C. 331(d)21 U.S.C. 353(b)21.U.S.C. 355(a)FD&C Act 201(g)21 U.S.C. 321(g)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dermax Co., Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.